Triple
T16946207
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Sovaldi |
E411074
|
entity |
| Predicate | usedInCombinationWith |
P4791
|
FINISHED |
| Object |
daclatasvir
Daclatasvir is a direct-acting antiviral medication used to treat chronic hepatitis C virus infection, typically as part of combination therapy.
|
E1242136
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: daclatasvir | Statement: [Sovaldi, usedInCombinationWith, daclatasvir]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: daclatasvir Context triple: [Sovaldi, usedInCombinationWith, daclatasvir]
-
A.
Epclusa
Epclusa is a prescription antiviral medication used to treat chronic hepatitis C infection across all major genotypes.
-
B.
Harvoni
Harvoni is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection.
-
C.
Sovaldi
Sovaldi is a breakthrough antiviral medication used to treat chronic hepatitis C by directly inhibiting the virus’s replication.
-
D.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
E.
velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: daclatasvir Triple: [Sovaldi, usedInCombinationWith, daclatasvir]
Generated description
Daclatasvir is a direct-acting antiviral medication used to treat chronic hepatitis C virus infection, typically as part of combination therapy.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: daclatasvir Target entity description: Daclatasvir is a direct-acting antiviral medication used to treat chronic hepatitis C virus infection, typically as part of combination therapy.
-
A.
Epclusa
Epclusa is a prescription antiviral medication used to treat chronic hepatitis C infection across all major genotypes.
-
B.
Harvoni
Harvoni is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection.
-
C.
Sovaldi
Sovaldi is a breakthrough antiviral medication used to treat chronic hepatitis C by directly inhibiting the virus’s replication.
-
D.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
E.
velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d886c886688190967be07322597ac9 |
completed | April 10, 2026, 5:12 a.m. |
| NER | Named-entity recognition | batch_69e3cfb25e0c8190948e62d9575ae9cd |
completed | April 18, 2026, 6:38 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_6a00cfeca4208190a3b9270869063d3d |
completed | May 10, 2026, 6:35 p.m. |
| NEDg | Description generation | batch_6a00d0b13f1c819091f3f8b966e36214 |
completed | May 10, 2026, 6:38 p.m. |
| NED2 | Entity disambiguation (via description) | batch_6a00d1ad6b7081908be76d70ad9e2075 |
completed | May 10, 2026, 6:42 p.m. |
Created at: April 10, 2026, 5:31 a.m.